Cargando…
Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348454/ https://www.ncbi.nlm.nih.gov/pubmed/36869702 http://dx.doi.org/10.1210/clinem/dgad095 |
| _version_ | 1785073670081740800 |
|---|---|
| author | Miller, Bradley S Blair, Joanne C Rasmussen, Michael Højby Maniatis, Aristides Kildemoes, Rasmus Juul Mori, Jun Polak, Michel Bang, Rikke Beck Böttcher, Volker Stagi, Stefano Horikawa, Reiko |
| author_facet | Miller, Bradley S Blair, Joanne C Rasmussen, Michael Højby Maniatis, Aristides Kildemoes, Rasmus Juul Mori, Jun Polak, Michel Bang, Rikke Beck Böttcher, Volker Stagi, Stefano Horikawa, Reiko |
| author_sort | Miller, Bradley S |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10348454 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103484542023-07-15 Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial” Miller, Bradley S Blair, Joanne C Rasmussen, Michael Højby Maniatis, Aristides Kildemoes, Rasmus Juul Mori, Jun Polak, Michel Bang, Rikke Beck Böttcher, Volker Stagi, Stefano Horikawa, Reiko J Clin Endocrinol Metab Invited Letter to the Editor Response Oxford University Press 2023-03-03 /pmc/articles/PMC10348454/ /pubmed/36869702 http://dx.doi.org/10.1210/clinem/dgad095 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Invited Letter to the Editor Response Miller, Bradley S Blair, Joanne C Rasmussen, Michael Højby Maniatis, Aristides Kildemoes, Rasmus Juul Mori, Jun Polak, Michel Bang, Rikke Beck Böttcher, Volker Stagi, Stefano Horikawa, Reiko Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial” |
| title | Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial” |
| title_full | Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial” |
| title_fullStr | Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial” |
| title_full_unstemmed | Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial” |
| title_short | Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial” |
| title_sort | response to letter to the editor from chatelain et al: “weekly somapacitan is effective and well tolerated in children with gh deficiency: the randomized phase 3 real4 trial” |
| topic | Invited Letter to the Editor Response |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348454/ https://www.ncbi.nlm.nih.gov/pubmed/36869702 http://dx.doi.org/10.1210/clinem/dgad095 |
| work_keys_str_mv | AT millerbradleys responsetolettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial AT blairjoannec responsetolettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial AT rasmussenmichaelhøjby responsetolettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial AT maniatisaristides responsetolettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial AT kildemoesrasmusjuul responsetolettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial AT morijun responsetolettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial AT polakmichel responsetolettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial AT bangrikkebeck responsetolettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial AT bottchervolker responsetolettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial AT stagistefano responsetolettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial AT horikawareiko responsetolettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial |